Home > Healthcare > Pharmaceuticals > Pharma Manufacturing > Topical Drugs CDMO Market

Topical Drugs CDMO Market Trends

Report ID: GMI9137
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Topical Drugs CDMO Market Trends

Technological advancements in formulation technology and transdermal drug delivery systems are propelling this trend forward. Innovative technologies, including nanoparticle-based topical treatments, liposomes, and microencapsulation, are enhancing the bioavailability and therapeutic efficacy of topical drugs. This enhancement makes them more attractive for treating a broader range of conditions, from chronic skin issues like eczema and psoriasis treatment to pain management and hormonal therapies.

Moreover, the growth of the topical drugs contract development and manufacturing organization (CDMO) market is primarily driven by the increasing demand for dermatological treatments, which is fuelled by a rising prevalence of skin conditions. The global CDMO market for topical drugs is expanding as pharmaceutical companies seek specialized partners to meet the high standards required for formulation, regulatory compliance, and scale-up.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global topical drugs CDMO industry was valued at USD 43.7 billion in 2023 and is estimated to grow at a CAGR of over 10.5% from 2024 to 2032, driven by an increasing focus on non-invasive drug delivery systems.

The semi-solid segment accounted for USD 27.3 billion in 2023, with formulations such as creams, ointments, and gels gaining prominence due to their effectiveness in treating various skin conditions.

U.S. topical drugs CDMO industry is expected to grow at a 10.1% CAGR, reaching USD 35 billion by 2032, supported by the presence of leading CDMOs that enhance the production of high-quality topical products.

Key players in the industry include Ascendia Pharmaceuticals, Bora Pharmaceuticals, Cambrex, Contract Pharmaceuticals, DPT Laboratories, MedPharm, PCI Pharma Services, Pierre Fabre Group, Piramal Pharma Solutions, and The Lubrizol.